Outlook Therapeutics reports Q2 net loss $6.7M; PDUFA date Aug 29 for ONS-5010

Outlook Therapeutics, Inc.

2023-Q2 EPS reported -$0.10

Net loss $6.7M ($0.03/sh) vs $19.7M ($0.09) in prior-year Q2.
Cash $43.7M as of March 31, 2023; expects to fund ops through potential approval in Q3/Q4 2023.
PDUFA goal date Aug 29, 2023 for ONS-5010 (bevacizumab) for wet AMD.
Pre-launch commercial activities ongoing; partnership with AmerisourceBergen for distribution.
MAA for ONS-5010 under EU review; CHMP decision expected early 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Outlook Therapeutics, Inc. reported financial results for second fiscal quarter ended March 31, 2023.

Period: second fiscal quarter ended March 31, 2023
Result: reported results

Exact text from the filing

On May 15, 2023, Outlook Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for its second fiscal quarter ended March 31, 2023.

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

Outlook Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-060850

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.